Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PXN antisense RNA 1 (non-protein coding) (PXN-AS1)
- Target
- PXN-AS1
- Molecular classification
- Other, Long non-coding RNA, Antisense lncRNA
01
Overview
PXN antisense RNA 1 is a long non-coding RNA located on chromosome 12 (hg38: chr12:120201260-120213401), transcribed opposite to the Paxillin (PXN) gene. It undergoes alternative splicing regulated by MBNL3, resulting in at least two major transcript isoforms (PXN-AS1-L and PXN-AS1-S). PXN-AS1-L upregulates PXN protein levels by stabilizing PXN mRNA, particularly via direct binding to the 3’UTR and protection against miRNA-induced degradation. PXN-AS1-S can decrease PXN mRNA translation. Together, their interplay helps maintain PXN homeostasis in adult liver tissue, and their dysregulation is implicated in the progression of hepatocellular carcinoma and other cancers. PXN-AS1 may serve as a biomarker for poor prognosis in cancer patients and as a putative therapeutic target due to its critical role in cancer biology.
- Other names
- EyeLinc4PXN-AS1PXN antisense RNA 1 (non-protein coding)
02
Mechanism of action
Not applicable (No drugs target PXN-AS1 yet; mechanistic actions are described in terms of molecular functions: e.g. sponging miRNAs, modulating stability and translation of PXN mRNA)
03
Biological functions
Regulation of PXN mRNA stabilityModulation of alternative splicingPost-transcriptional gene regulationCompeting endogenous RNA (ceRNA) function (miRNA sponging)Chromatin and transcriptional regulation
04
Disease associations
Cancer (particularly hepatocellular carcinoma, triple-negative breast cancer, and possibly others based on the role of antisense lncRNAs in tumorigenesis)Other roles are emerging but not clearly established outside oncology
05
Safety considerations
Not well established (Therapeutic challenges may include delivery and specificity if targeting PXN-AS1, but no actual safety profile exists due to lack of clinical therapeutics)
06
Biomarkers
High expression of PXN-AS1 itself may serve as a biomarker for poor prognosis in hepatocellular carcinoma and possibly other cancers
Beyond the preview
Go deeper on PXN antisense RNA 1 (non-protein coding) (PXN-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PXN antisense RNA 1 (non-protein coding) (PXN-AS1).